Brokers Offer Predictions for Allogene Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLOFree Report) – Zacks Research increased their Q1 2024 EPS estimates for shares of Allogene Therapeutics in a note issued to investors on Tuesday, February 6th. Zacks Research analyst S. Ganoria now expects that the company will earn ($0.48) per share for the quarter, up from their prior estimate of ($0.50). The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($2.03) per share. Zacks Research also issued estimates for Allogene Therapeutics’ Q2 2024 earnings at ($0.49) EPS, Q3 2024 earnings at ($0.49) EPS, Q4 2024 earnings at ($0.50) EPS, FY2024 earnings at ($1.96) EPS, Q1 2025 earnings at ($0.50) EPS, Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($2.03) EPS.

ALLO has been the topic of a number of other reports. HC Wainwright decreased their target price on Allogene Therapeutics from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, January 19th. JMP Securities reaffirmed a “market perform” rating on shares of Allogene Therapeutics in a report on Friday, January 5th. Citigroup initiated coverage on shares of Allogene Therapeutics in a research note on Friday, December 8th. They issued a “buy” rating and a $7.00 price target on the stock. Finally, Guggenheim downgraded shares of Allogene Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, January 5th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $15.29.

Check Out Our Latest Stock Analysis on Allogene Therapeutics

Allogene Therapeutics Stock Up 1.0 %

Shares of NASDAQ ALLO opened at $4.15 on Thursday. The business’s 50 day moving average price is $3.11 and its two-hundred day moving average price is $3.39. The company has a market cap of $698.36 million, a PE ratio of -1.85 and a beta of 0.73. Allogene Therapeutics has a twelve month low of $2.23 and a twelve month high of $7.75.

Insider Activity

In other news, Director Deborah M. Messemer sold 18,640 shares of Allogene Therapeutics stock in a transaction on Monday, December 18th. The stock was sold at an average price of $2.70, for a total value of $50,328.00. Following the transaction, the director now owns 62,456 shares in the company, valued at approximately $168,631.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 27.40% of the company’s stock.

Institutional Investors Weigh In On Allogene Therapeutics

Several hedge funds have recently modified their holdings of the company. McGlone Suttner Wealth Management Inc. bought a new position in shares of Allogene Therapeutics during the fourth quarter valued at $27,000. EP Wealth Advisors LLC bought a new position in Allogene Therapeutics during the 3rd quarter worth $34,000. Aaron Wealth Advisors LLC bought a new position in Allogene Therapeutics during the 4th quarter worth $34,000. Axxcess Wealth Management LLC acquired a new position in Allogene Therapeutics during the 4th quarter worth about $34,000. Finally, GTS Securities LLC bought a new stake in shares of Allogene Therapeutics in the 3rd quarter valued at about $35,000. Institutional investors and hedge funds own 78.51% of the company’s stock.

About Allogene Therapeutics

(Get Free Report)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.

Featured Articles

Earnings History and Estimates for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.